What We Do

Our Mission is to help solve one of the greatest challenges of modern medicine today: the global shortage of organs and tissues for transplants.

 

Xenotransplantation (the process of grafting or transplanting organs and tissues between members of different species) has the ability to provide an unlimited supply of critically needed tissues and organs from genetically engineered animals.  

 

XenoTherapeutics combines fundamental principles with proven technologies in the field of xenotransplantation to provide humanized soft tissue solutions to patients in critical need.

 

Our product platform begins with skin, but we envision multiple xenotransplantation solutions that will address the current worldwide shortage of transplant products.

 

Our approach is efficient, cost-effective and patient-driven.

XENO-SKIN™

XenoTherapeutics' First Non-Human Organ Transplant Solution

BURN CARE EDUCATION

Learn More About Burn Care

Learn More About Organ Procurement

 

Who We Are

We are a focused team of experts in the field of xenotransplantation, including advisors from the world’s leading medical and scientific institutions who possess vast experience in the fields of surgery and infectious disease.

Our Business Model

Learn More About Business Structure

 

BOARD OF DIRECTORS

SCIENTIFIC ADVISORS

PAUL BARRETT

Founding Chairman

WILLIAM DEACON

Founding Vice President

DR. MICHAEL YAREMCHUK

Founding Board Member

PAM LAYTON

Board Member

DR. DICKEN KO

Board Member

MICHAEL MANO

Board Member

 

DR. LINDA SCOBIE

Infectious Disease Advisor

DR. ROB KAISER, DABT

Infectious Scientific Advisor

 

EXECUTIVE STAFF

KAITLYN ROGERS

Project Director

JEMMA PELLING

Executive Assistant

 

 

"In 1982, our senior colleague, Thomas Starzl, one of the great pioneers of allotransplantation, wrote: ‘History tells us that procedures which were inconceivable yesterday, and are barely achievable today, often become routine tomorrow.’

 

We believe that, with the novel genetically-engineered pigs becoming available to us, clinical pig organ and cell transplantation, inconceivable only a few years ago and barely achievable today, will become routine tomorrow. Indeed, allotransplantation will eventually become of historic interest only."

—  David Cooper, David Ayares - The role of genetically engineered pigs in  xenotransplantation research; Journal of Pathology, 2016: 288-299

QUOTES

 
Contact Us
Contact Information

Innovation Office & Mailing Address 
359 Newbury St
Boston MA 02115

 

 

Tel: 617-939-7892

Email: info@xenotherapeutics.org

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon

© 2019 by  XenoTherapeutics. All Rights Reserved.

xenotransplantation; xenograft; burns; biotechnology; wound; organs; skin graft; burn treatment; transplant; organ donation;